2 recruiting, 1 active not recruiting, 1 completed. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Active not recruiting 1, Completed 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Ikaria Bioscience Pty Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers RN5681, Placebo control - High Cholesterol | Phase 1 | Recruiting | Ikaria Bioscience Pty Ltd | 60 | 2026-03-12 | 2026-04-03 |
| Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity RN3161, Placebo Control, Tirzepatide - Obesity &Amp; Overweight | Phase 1 / Phase 2 | Recruiting | Ikaria Bioscience Pty Ltd | 104 | 2025-11-04 | 2025-11-24 |
| Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects RN0361 - Hypertriglyceridemia, Familial Chylomicronemia Syndrome | Phase 1 / Phase 2 | Active not recruiting | Ikaria Bioscience Pty Ltd | 108 | 2024-09-30 | 2025-12-30 |
| Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects RN0191 INJECTION - To Reduce the LDL-C Level in Hypercholesteremia Adult Patients, Combination for Subgroup High LDL-c Patients With Other Comorbidities | Phase 1 | Completed | Ikaria Bioscience Pty Ltd | 32 | 2023-07-14 | 2024-10-10 |
Familial hyperchylomicronemia syndrome (1) · Hypercholesterolemia (1) · Hypertriglyceridemia (1) · Obesity (1) · Overweight (1)
Tirzepatide (1)
Australia (4) · United States (1)
Kristi McLendon, MD (1) · Philip Ryan, MD (1)